2Te HS,Jensen DM.Epidemiology of hepatitis B and C viruses:a global overview[J].Clin Liver Dis,2010,14(1):1-21.
3onopnicki D,Mocroft A,deWit S,et al.Hepatitis B and HIV:prevalence,AIDS progression,response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort[J].AIDS,2005,19(6):2117-2125.
4Chun HM,Fieberg AM,Hullsiek KH,et al;Infectious Disease Clinical Research Program HIV Working Group.Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past20years[J].Clin Infect Dis,2010,50(3):426-436.
5Kellerman S,Hanson DL,McNaghten AD,et al.Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunode ciency virus-infected subjects[J].J Infect Dis,2003,188(4):571-577.
6Lok AS,Heathcote EJ,Hoofnagle JH.Management of hepatitis B:2000-summaryofaworkshop[J].Gastroenterology,2001,120(7):1828-1853.
7European AIDS Clinical Society.European AIDS Clinical Society Guidelines[R/OL].Version6.0,October,2011.Available at:http://www.europeanaidsclinicalsociety.org.
8Torriani FJ,Rodriguez-Torres M,Rockstroh JK,et al.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients[J].N Engl J Med,2004,351(5):438-450.
9European AIDS Clinical Society.European HIV Drug Resistance Guidelines[R/OL].Version6.0,October,2011.Available at:http://www.europeanaidsclinicalsociety.org.
10Benhamou Y,Bochet M,Thibault V,et al.Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients[J].Hepatology,1999,30(5):1302-1306.
